MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

131.47 +1.74 (+1.34%)
Streaming Delayed Price Updated: 1:05 PM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 757,395
Open 133.64
Bid (Size) 131.46 (300)
Ask (Size) 132.00 (200)
Prev. Close 129.73
Today's Range 129.11 - 135.07
52wk Range 5.620 - 148.83
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
2 Stocks That Could Realistically Double by 2030 ↗
Long-time shareholders are already pretty satisfied with these companies, but there might be even more upside ahead. 
Via The Motley Fool

Performance

YTD
-1.7%
-1.7%
1 Month
+17.5%
+17.5%
3 Month
+6.6%
+6.6%
6 Month
+4.6%
+4.6%
1 Year
+2210.5%
+2210.5%

More News

Read More
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
Via The Motley Fool
News headline image
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
Via The Motley Fool
News headline image
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Abivax Announces Results of its May 11, 2026 Annual General Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
News headline image
Abivax to Present Data on Obefazimod at Digestive Disease Week®
From Abivax
Via GlobeNewswire
News headline image
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
From Abivax
Via GlobeNewswire
News headline image
This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy? ↗
Via The Motley Fool
News headline image
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
From Abivax
Via GlobeNewswire
News headline image
2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗
Via The Motley Fool
News headline image
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
From Abivax
Via GlobeNewswire
News headline image
Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Healthcare Stocks to Buy Before They Get Bought Out ↗
Via The Motley Fool
News headline image
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
Via The Motley Fool
News headline image
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗
Via The Motley Fool

Frequently Asked Questions

Is Abivax SA - American Depositary Shares publicly traded?
Yes, Abivax SA - American Depositary Shares is publicly traded.
What exchange does Abivax SA - American Depositary Shares trade on?
Abivax SA - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Abivax SA - American Depositary Shares?
The ticker symbol for Abivax SA - American Depositary Shares is ABVX on the Nasdaq Stock Market
What is the current price of Abivax SA - American Depositary Shares?
The current price of Abivax SA - American Depositary Shares is 131.47
When was Abivax SA - American Depositary Shares last traded?
The last trade of Abivax SA - American Depositary Shares was at 05/28/26 01:05 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story